{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:07:04Z","timestamp":1782284824179,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ab.2011.09.030","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T23:49:31Z","timestamp":1318549771000},"page":"351-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein"],"prefix":"10.1016","volume":"421","author":[{"given":"Q.","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Silberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bettencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2011.09.030_b0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ab.2011.09.030_b0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tibtech.2007.07.005","article-title":"Antibody cocktails: next-generation biopharmaceuticals with improved potency","volume":"25","author":"Logtenberg","year":"2007","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ab.2011.09.030_b0015","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/j.vaccine.2008.08.050","article-title":"First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity","volume":"26","author":"Bakker","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ab.2011.09.030_b0020","doi-asserted-by":"crossref","first-page":"e5672","DOI":"10.1371\/journal.pone.0005672","article-title":"Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants","volume":"4","author":"Prabakaran","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ab.2011.09.030_b0025","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1128\/IAI.00200-09","article-title":"Novel chimpanzee\/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody","volume":"77","author":"Chen","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ab.2011.09.030_b0030","series-title":"The Challenge of Highly Pathogenic Microorganisms","first-page":"275","article-title":"Combination of anthrax\u2013toxin neutralizing antibodies: analysis of synergism\/antagonism effect","author":"Mazor","year":"2010"},{"key":"10.1016\/j.ab.2011.09.030_b0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1158\/0008-5472.CAN-09-1417","article-title":"Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy","volume":"70","author":"Pedersen","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ab.2011.09.030_b0040","unstructured":"European Union, Production and quality control of monoclonal antibodies, directive 75\/318\/EEC, 1995, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003444.pdf>."},{"key":"10.1016\/j.ab.2011.09.030_b0045","unstructured":"U.S. Department of Health and Human Services, Points to consider in the manufacture and testing of monoclonal antibody products for human use, 1997, <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/OtherRecommendationsforManufacturers\/UCM153182.pdf>."},{"key":"10.1016\/j.ab.2011.09.030_b0050","first-page":"42","article-title":"CMC Strategy Forum Report: analysis and structure characterization of monoclonal antibodies","volume":"2","author":"Schenerman","year":"2004","journal-title":"BioProcess Int."},{"key":"10.1016\/j.ab.2011.09.030_b0055","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.chroma.2010.10.107","article-title":"Separation of oxidized variants of a monoclonal antibody by anion-exchange","volume":"1218","author":"Teshima","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ab.2011.09.030_b0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1515\/JPEM.2001.14.4.389","article-title":"Measurements of bone turnover markers in premature infants","volume":"14","author":"Shiff","year":"2001","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ab.2011.09.030_b0065","first-page":"275","article-title":"Bioterrorism in Canada: an economic assessment of prevention and postattack exposure","volume":"12","author":"St. John","year":"2001","journal-title":"Can. J. Infect. Dis."},{"key":"10.1016\/j.ab.2011.09.030_b0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(80)90469-6","article-title":"Hypersensitivity reactions associated with botulinal antitoxin","volume":"69","author":"Black","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ab.2011.09.030_b0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/clinids\/23.2.337","article-title":"Experience with the use of an investigational F(ab\u2032)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E origin in Egypt","volume":"23","author":"Hibbs","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ab.2011.09.030_b0080","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1073\/pnas.172229899","article-title":"Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody","volume":"99","author":"Nowakowski","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ab.2011.09.030_b0085","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.130.3378.763","article-title":"The most poisonous poison","volume":"130","author":"Lamanna","year":"1959","journal-title":"Science"},{"key":"10.1016\/j.ab.2011.09.030_b0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jim.2007.06.011","article-title":"Evaluation of a peptide ELISA for the detection of rituximab in serum","volume":"325","author":"Blasco","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ab.2011.09.030_b0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ab.2009.05.030","article-title":"Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma","volume":"391","author":"Damen","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ab.2011.09.030_b0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jim.2007.08.008","article-title":"Isolation of human anti-idiotypic antibodies by phage display for clinical immune response assays","volume":"328","author":"Tornetta","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ab.2011.09.030_b0105","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/0022-1317-73-3-653","article-title":"Construction of solid matrix\u2013antibody\u2013antigen complexes containing Simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen","volume":"73","author":"Hanke","year":"1992","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ab.2011.09.030_b0110","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ab.2011.09.030_b0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmb.2006.09.084","article-title":"Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display","volume":"365","author":"Levy","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ab.2011.09.030_b0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/abio.1999.4176","article-title":"Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution","volume":"272","author":"Blake","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ab.2011.09.030_b0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/protein\/gzq001","article-title":"Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating","volume":"23","author":"Lou","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ab.2011.09.030_b0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jmb.2005.06.003","article-title":"Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A","volume":"351","author":"Razai","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ab.2011.09.030_b0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0003-2697(84)90773-5","article-title":"Colorimetric assay for monoamine oxidase in tissues using peroxidase and 2,2\u2032-azinodi(3-ethylbenzthiazoline-6-sulfonic acid) as chromogen","volume":"138","author":"Szutowicz","year":"1984","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ab.2011.09.030_b0140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0161-5890(80)90150-9","article-title":"Monoclonal antibodies to human \u03b1-fetoprotein","volume":"17","author":"Uotila","year":"1980","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ab.2011.09.030_b0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0022-1759(83)90269-7","article-title":"Assessment of substrates for horseradish peroxidase in enzyme immunoassay","volume":"58","author":"Al-Kaissi","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ab.2011.09.030_b0150","series-title":"Encyclopedia of Analytical Chemistry","article-title":"Chemiluminescence, electrogenerated","author":"Bard","year":"2000"},{"key":"10.1016\/j.ab.2011.09.030_b0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nbt1269","article-title":"Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin","volume":"25","author":"Garcia-Rodriguez","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ab.2011.09.030_b0160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.pep.2005.07.020","article-title":"Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A","volume":"45","author":"Sharma","year":"2006","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ab.2011.09.030_b0165","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/IAI.01252-08","article-title":"Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes","volume":"77","author":"Shone","year":"2009","journal-title":"Infect. Immun."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269711006397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269711006397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T21:05:10Z","timestamp":1757711110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269711006397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0003269711006397"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2011.09.030","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2011.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}